Figure 3. Median Percentage Reduction From Baseline in 28-Day Frequency of FIAS and TCS, Patients With Coexisting ASD

Figure 3 % reduction in seizures from baseline ASD

Median Percentage Reduction From Baseline in 28-Day Frequency of FIAS and TCS by Time Point, Patients With Coexisting ASD at Baseline

Format

PNG

Source

Zynerba Pharmaceuticals, Inc.

Downloads